VA-VIRTUSTREAM
9.10.2020 13:02:06 CEST | Business Wire | Press release
Virtustream, an enterprise-class cloud company and Dell Technologies business, announced xStreamCare Services for Security and Compliance today, bringing together advanced security management and monitoring, expert consulting services, and its innovative Trust Platform – a unified, security and compliance management platform.
Virtustream’s latest security solutions provide near real-time visibility into security alerts, intrusion attempts, open vulnerabilities, log analytics, policy management and entitlements across Virtustream’s Enterprise Cloud and Healthcare Cloud platforms, enabling enterprises to achieve a more proactive security posture to protect their business’ IT assets, applications and data.
“Setting the standards of excellence is important to our team at Benjamin Moore. Not only for our products and color offerings, but also for IT security,” said Syed Haider, Director of IT Security, Benjamin Moore. “Virtustream’s deep cloud expertise and focus on understanding our business’ needs make it an excellent fit for us. And by leveraging Virtustream’s new Trust Platform and comprehensive security services – with clear visibility all in one place – we can seamlessly address any issues or risks that may arise.”
For most customers, deploying security services is a manual process, typically managed through multiple platforms. This can be time-consuming, complex and expensive. Without a means to consolidate security data, enterprises struggle to identify their security, compliance and business risks as a whole. In fact, a recent study by Ponemon Institute1 found that 56% of businesses say data breaches occur because of a lack of visibility into the operations of their security programs.
“Our comprehensive approach to security is built on more than a decade of mission-critical cloud experience. With our new security offerings, you can eliminate the need to internally manage the growing number of complexities, cyberattacks and regulatory requirements,” says Pritesh Parekh, Chief Trust & Security Officer at Virtustream. “Our xStreamCare Services for Security and Compliance allow our customers to attain a more robust proactive security posture with unified, near real-time visibility, enabling them to quickly set priorities and make more informed security decisions with precision.”
Unified View Delivers Enhanced Insights and Faster Response Times
Virtustream’s Trust Platform aggregates and automates security data into a unified dashboard. The platform’s simplified and comprehensive view eliminates the need to manually aggregate and process logs from multiple tools and services by providing a clean, near real-time view of an enterprise’s security posture, compliance and risk across multiple workloads.
Virtustream’s Trust Platform is based on the company’s decade of experience securing mission-critical data and applications in the cloud. Further setting the new solution apart from other industry offerings are advanced features, including:
Alerts Dashboard : Displays security alerts with sensitivity levels that originate from Virtustream-deployed security controls with the ability to drill down, filter, and export data.
Vulnerability Dashboard : Prompts proactive protection through awareness of open vulnerabilities as well as their severity and age. Authorized users can define and manage aging and remediation policies.
Log Analytics : Enables ad-hoc queries against aggregated security and OS logs.
Policy Management: Supports customer-defined policies for managing security vulnerabilities.
Compliance Reporting : Allows on-demand download of available reports such as Type 2 SOC 2 + HITRUST with Cloud Security Alliance (CSA) Cloud Controls Matrix and Type 2 Attestation (AT-C 105 and AT-C 205) HIPAA/HITECH.
Asset Management Dashboard : Catalogs all assets in the cloud along with the status of security services.
The Trust Platform is available today on Virtustream Enterprise Cloud and Virtustream Healthcare Cloud.
Security Services for Every Businesses’ IT Needs
The combination of robust security features with actionable visibility helps block attacks proactively before they can penetrate a secure environment. Using security services for cloud-hosted mission-critical applications can also help increase the internal security operation team’s productivity. By off-loading management, internal IT teams can reduce the daily burden of managing security operations. Internal teams can also leverage on-demand access to certified cybersecurity experts and consulting services to address a range of potential internal skills gap.
The Security Essentials Bundle includes anti-virus/anti-malware, host intrusion detection system (IDS), host firewall, host file integrity monitoring, log management and vulnerability scanning. The Security Healthcare Bundle includes all services from the Essentials set as well as data at rest encryption and network intrusion detection. And the Enhanced Bundle includes all of these services along with log forwarding, network firewall policy auditor, data at rest encryption, operating system hardening scans, and SAP virus scanning services.
Find more information on Virtustream Enterprise Cloud , Virtustream Healthcare Cloud , the Trust Center , and on xStreamCare Services for Security and Compliance .
About Virtustream
Virtustream LLC, a Dell Technologies Business, is the enterprise-class cloud company that is trusted by organizations worldwide to migrate and run their mission-critical applications in the cloud. For enterprises, service providers, healthcare organizations and government agencies Virtustream’s xStreamCare Services™ expertise combined with the Virtustream xStream® Management Platform and Infrastructure-as-a Service (IaaS) meets the security, compliance, performance, efficiency and consumption-based billing requirements of complex production applications in the cloud – whether private, public or hybrid.
Virtustream is a trademark of Virtustream LLC. Other trademarks may be trademarks of their respective owners.
1) “The Cybersecurity Illusion: The Emperor Has No Clothes,” by Ponemon Institute, published in July 2019, cited here on Nov. 6, 2019.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201009005040/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 202622.5.2026 11:18:00 CEST | Press release
Ellipses Pharma (“Ellipses”), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for EP0031/A400, for the potential treatment of RET-fusion positive Non-Small Cell Lung Cancer (NSCLC), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, May 29 to June 2. Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase Ⅱ study in patients with advanced RET-fusion positive non-small cell lung cancer (NSCLC), will be presented as an oral presentation scheduled on May 29, 2026, 14:36-14:48 local time (Abstract #8505: Lung Cancer – Non-Small Cell Metastatic). The oral presentation of these data at the prestigious ASCO annual meeting, represents another major milestone in the global development of EP0031/A400 as a next generation SRI. The data were generated in Kelun-Biotech’s Phase 2 study (NCT0
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
